novo nordisk semaglutide lawsuit expands lawsuits in U.S. against weight-loss drug compounders Novo Nordisk, maker of the

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial

E.FlouriF.MalandrakisA

The authors hypothesized that the drug lowers migraine frequency by reducing intracranial pressure

Fast and well packaged

Rotating injection sites between the abdomen and thighs helps minimize this issue

Increase Oversight of Facilities Require larger compounding facilities to be inspected before operating and regularly after Require medical spas offering weight-loss drugs to register and have a responsible practitioner physically present 4